

UPDATE OF 17 MARCH 2023

(most recently added papers are marked in blue)

Coordinated by:

ANRS-EID/I3M: Erica Telford & Eric D'Ortenzio

*Documented by (until Sept. 2020):
Inserm- Collective Expertise Unit:
Bénédicte Varignon & Laurent Fleury*

Redaction Committee :

*ANRS-Emerging Infectious Diseases:
Guia Carrara; Mario Delgado-Ortega; Erica Telford*

With a precious contribution from:

• Former members of the redaction committee: Claire Brugerolles; Eric D'Ortenzio; Evelyne Jouvin-Marche; Boris Lacarra; Claire Madelaine; Inmaculada Ortega-Perez; Xyomara Chavez-Pacheco; Oriane Puéchal; Renaud Vatrinet • Inserm- Department of Partnerships and External Relations (DPRE) • Inserm- USA office • The MODCOV19 Team

Journal	Date	Title (Hyperlink)	Authors and doi	Country	Field of expertise
JAMA Netw Open	2023.03.16	Analysis of Previous Infection, Vaccinations, and Anti-SARS-CoV-2 Antibody Titers and Protection Against Infection With the SARS-CoV-2 Omicron BA.5 Variant	Yamamoto S., et al. https://doi.org/10.1001/jamanetworkopen.2023.3370	Japan	Immunology
JAMA Netw Open	2023.03.16	Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods	Link-Gelles R., et al. https://doi.org/10.1001/jamanetworkopen.2023.2599	USA	Vaccines
Lancet Infect. Dis.	2023.03.15	Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system	Lewnard J.A., et al. https://doi.org/10.1016/S1473-3099(23)00118-4	USA	Therapeutics
JAMA Netw Open	2023.03.15	Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods	Link-Gelles R., et al. https://doi.org/10.1001/jamanetworkopen.2023.2598	USA	Vaccines
medRxiv	2023.03.15	Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection	Moyo-Gwete T., et al. https://doi.org/10.1101/2023.03.15.23287288	South Africa	Vaccines
Nature Commun.	2023.03.15	Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain	Takano T., et al. https://doi.org/10.1038/s41467-023-37128-1	Japan	Vaccines
Science Transl Med.	2023.03.15	Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination	Barateau V., et al. https://doi.org/10.1126/scitranslmed.ade0550	France	Immunology
BMJ	2023.03.15	Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP	Hulme W.J., et al. https://doi.org/10.1136/bmj-2022-072808	UK	Vaccines
Ann. Intern. Med.	2023.03.14	Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19	Yuk Fai Wan E., et al. https://doi.org/10.7326/M22-3057	Hong Kong/UK	Therapeutics
Nature Commun.	2023.03.14	Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome	Lewnard J.A., et al. https://doi.org/10.1038/s41467-023-37051-5	USA	Variants

Nature Commun.	2023.03.14	Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein	Calvaresi V., et al. https://doi.org/10.1038/s41467-023-36745-0	UK	Virology
PNAS	2023.03.14	Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age	Humbert M., et al. https://doi.org/10.1073/pnas.2220320120	Sweden	Immunology
Lancet Infect. Dis.	2023.03.13	Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study	Tan C.Y., et al. https://doi.org/10.1016/S1473-3099(23)00060-9	Singapore	Immunology
Clin Microbiol Infect.	2023.03.13	Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines; randomized trial, 3 months follow-up	Barda N., et al. https://doi.org/10.1016/j.cmi.2023.03.007	Israel	Vaccines
NPJ Vaccines	2023.03.11	Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine	Benkeser D., et al. https://doi.org/10.1038/s41541-023-00630-0	USA	Vaccines
Clin Infect Dis.	2023.03.11	Post-acute sequelae after SARS-CoV-2 infection by viral variant and vaccination status: a multicenter cross-sectional study	Kahlert C.R., et al. https://doi.org/10.1093/cid/ciad143	Switzerland	Long Covid
Lancet Infect. Dis.	2023.03.10	Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study	Chemaitelly H., et al. https://doi.org/10.1016/S1473-3099(23)00058-0	Singapore	Vaccines
Nature Commun.	2023.03.10	Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates	Pavot V., et al. https://doi.org/10.1038/s41467-023-36908-z	International / France	Vaccines
JAMA Network Open	2023.03.09	Comparison of Symptoms Associated With SARS-CoV-2 Variants Among Children in Canada	Summer M.W., et al. https://doi.org/10.1001/jamanetworkopen.2023.2328	Canada	Clinics
medRxiv	2023.03.09	COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history	Townsley H., et al. https://doi.org/10.1101/2022.07.07.22277367	UK	Clinics
Nature Commun.	2023.03.09	SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity	Jaycox J.R., et al. https://doi.org/10.1038/s41467-023-36686-8	USA	Immunology
PNAS	2023.03.09	Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection	Hariharan V.N., et al. https://doi.org/10.1073/pnas.2219523120	USA	Therapeutics
Lancet	2023.03.07	Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX – REVOLUTION trial	Maia I.S., et al. https://doi.org/10.1016/j.lana.2023.100466	Brazil	Therapeutics
Lancet Oncol.	2023.03.07	SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry	Cortellini A., et al. https://doi.org/10.1016/S1470-2045(23)00056-6	International Study	Vaccines
Nature Commun.	2023.03.07	Long-term gastrointestinal outcomes of COVID-19	Xu E., et al. https://doi.org/10.1038/s41467-023-36223-7	USA	Long Covid
Nature Commun.	2023.03.07	Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes	Grewal R., et al. https://doi.org/10.1038/s41467-023-36566-1	Canada	Vaccines

BMJ	2023.03.07	<u>Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records</u>	Xie Y., et al. https://doi.org/10.1136/bmj-2022-072705	USA	Therapeutics
PNAS	2023.03.07	<u>Nasal administration of anti-CD3 mAb (Foralumab) downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells in subjects with COVID-19</u>	Moreira T.G., et al. https://doi.org/10.1073/pnas.2220272120	USA	Therapeutics
medRxiv	2023.03.06	<u>Modelling the association between neutralizing antibody levels and SARS-CoV-2 viral dynamics : implications to define correlates of protection against infection</u>	Lingas G., et al. https://doi.org/10.1101/2023.03.05.23286816	France	Immunology
Nature Immunol.	2023.03.06	<u>Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course</u>	Muri J., et al. https://doi.org/10.1038/s41590-023-01445-w	International	Immunology
eBioMedicine	2023.03.02	<u>Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination</u>	Underwood A.P., et al. https://doi.org/10.1016/j.ebiom.2023.104475	Denmark	Immunology
Valneva	2022.03.02	<u>Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001</u>	https://valneva.com/press-release/valneva-provides-clinical-and-regulatory-updates-for-its-covid-19-vaccine-vla2001/	Press release	Vaccines
Clin Infect Dis.	2023.03.02	<u>Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 (COVID-19) Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout</u>	Lea A.N., et al. https://doi.org/10.1093/cid/ciad084	USA	Clinic
NEJM	2023.03.01	<u>Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines</u>	Dedong L., et al. https://doi.org/10.1056/NEJMc2216233	China	Vaccines
Nature Commun.	2023.02.28	<u>Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life</u>	Zerbo O., et al. https://doi.org/10.1038/s41467-023-36547-4	USA	Vaccines
PNAS	2023.02.28	<u>Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2</u>	Muñoz-Basagoiti J., et al. https://doi.org/10.1073/pnas.2214561120	International	Therapeutics
JAMA Netw Open.	2023.02.28	<u>Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves</u>	Doll M.K., et al. https://doi.org/jamanetworkopen.2023.1181	USA	Public health
JAMA Netw Open.	2023.02.28	<u>Portable Breath-Based Volatile Organic Compound Monitoring for the Detection of COVID-19 During the Circulation of the SARS-CoV-2 Delta Variant and the Transition to the SARS-CoV-2 Omicron Variant</u>	Sharma R., et al. https://doi.org/10.1001/jamanetworkopen.2023.0982	USA	Diagnostics
BMJ Medicine	2023.02.28	<u>Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort</u>	Tran V-T., et al. http://dx.doi.org/10.1136/bmjmed-2022-000229	France	Long Covid
Immunity	2023.02.27	<u>SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses</u>	Koutsakos M., et al. https://doi.org/10.1016/j.immuni.2023.02.017	Australia	Immunology
bioRxiv	2023.02.27	<u>Cutaneous jet-injection of naked mRNA vaccine induces robust immune responses without systemic vaccine spillage</u>	Abbasi S., et al. https://doi.org/10.1101/2023.02.27.530188	Japan	Vaccines
medRxiv	2023.02.26	<u>Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents</u>	Lopez P., et al. https://doi.org/10.1101/2023.02.22.23286317	International	Vaccines

Nature Commun.	2023.02.25	<u>Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2</u>	Higashi-Kuwata N., et al. https://doi.org/10.1038/s41467-023-36729-0	Japan	Therapeutics
medRxiv	2023.02.24	<u>Safety of the NVX-CoV2373 COVID-19 Vaccine in Randomized Placebo-Controlled Clinical Trials</u>	Smith K., et al. https://doi.org/10.1101/2023.02.24.23285601	USA	Vaccines
Science Immunol.	2023.02.23	<u>Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19</u>	Zhu B., et al. https://doi.org/10.1126/sciimmunol.adf0348	USA	Therapeutics
Nature Commun.	2023.02.22	<u>Epidemiological impacts of the NHS COVID-19 app in England and Wales throughout its first year</u>	Kendall M., et al. https://doi.org/10.1038/s41467-023-36495-z	UK	Public Health / Epidemiology
Clin Infect Dis.	2023.02.22	<u>The COVID-19 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated with Nirmatrelvir Plus Ritonavir Versus Untreated Controls</u>	Pandit J.A., et al. https://doi.org/10.1093/cid/ciad102	USA	Therapeutics
JAMA	2023.02.22	<u>Effect of Higher-Dose Ivermectin for 6 Days vs. Placebo on Time to Sustained Recovery in Outpatients With COVID-19</u>	Naggie S., et al. https://doi.org/10.1001/jama.2023.1650	USA	Therapeutics
Gilead	2023.02.21	<u>Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients</u>	https://www.gilead.com/news-and-press/press-room/press-releases/2023/2/veklury-remdesivir-reduced-risk-of-mortality-in-hospitalized-covid19-patients-across-all-variant-time-periods-in-a-real-world-study-of-more-than-5	Press release	Therapeutics
Lancet Respir Med.	2023.02.21	<u>Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials</u>	Amstutz A., et al. https://doi.org/10.1016/S2213-2600(22)00528-8	International (France)	Therapeutics
Ann Intern Med.	2023.02.21	<u>Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection</u>	Deo R., et al. https://doi.org/10.7326/M22-2381	USA	Clinic
Nature Metab.	2023.02.20	<u>Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity</u>	Yoshiji S., et al. https://doi.org/10.1038/s42255-023-00742-w	International	Clinic
Lancet Regional Health Americas	2023.02.19	<u>Safer at school early alert: an observational study of wastewater and surface monitoring to detect COVID-19 in elementary schools</u>	Fielding-Miller R., et al. https://doi.org/10.1016/j.lana.2023.100449	USA	Public health / Epidemiology
Lancet Child Adolesc Health	2023.02.17	<u>Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3–17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial</u>	Gao L., et al. https://doi.org/10.1016/S2352-4642(22)00376-5	China	Vaccines
medRxiv	2023.02.16	<u>Estimates of protection against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season - the IMMUNEBRIDGE project</u>	Lange B., et al. https://doi.org/10.1101/2023.02.16.23285816	Germany	Immunology
Lancet Microbe	2023.02.15	<u>Peptide microarray IgM and IgG screening of pre-SARS-CoV-2 human serum samples from Zimbabwe for reactivity with peptides from all seven human coronaviruses: a cross-sectional study</u>	Ashworth J., et al. https://doi.org/10.1016/S2666-5247(22)00295-6	International	Immunology
NEJM	2023.02.16	<u>Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age</u>	Muñoz F.M., et al. https://doi.org/10.1056/NEJMoa2211031	International	Vaccines
NEJM	2023.02.15	<u>Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis</u>	Huth L., et al. https://doi.org/10.1056/NEJMc2216309	Germany	Vaccines

Science Transl Med.	2023.02.15	<u>An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination</u>	Carreño J.M., et al. https://doi.org/10.1126/scitranslmed.abo2847	Thailand / USA	Vaccines
Science Transl Med.	2023.02.15	<u>Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose</u>	Filardi B.A., et al. https://doi.org/10.1126/scitranslmed.ade6023	Brazil / USA	Vaccines
Immunity	2023.02.15	<u>Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease</u>	Zhou P., et al. https://doi.org/10.1016/j.immuni.2023.02.005	USA	Immunology
Lancet Global Health	2023.02.15	<u>Genomic epidemiology of SARS-CoV-2 infections in The Gambia: an analysis of routinely collected surveillance data between March, 2020, and January, 2022</u>	Kanteh A., et al. https://doi.org/10.1016/S2214-109X(22)00553-8	The Gambia	Public Health / Epidemiology
Nature Commun.	2023.02.14	<u>Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies</u>	Planas D., et al. https://doi.org/10.1038/s41467-023-36561-6	France	Immunology
JAMA Netw Open	2023.02.14	<u>Association of COVID-19 Vaccination With Risk for Incident Diabetes After COVID-19 Infection</u>	Kwan A.C., et al. https://doi.org/10.1001/jamanetworkopen.2022.55965	USA	Clinic
Nature Commun.	2023.02.13	<u>Emergence and spread of two SARS-CoV-2 variants of interest in Nigeria</u>	Olawoye I.B., et al. https://doi.org/10.1038/s41467-023-36449-5	Nigeria / USA	Variants
Lancet Infect Dis.	2023.02.13	<u>Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study</u>	Wong C.K.H., et al. https://doi.org/10.1016/S1473-3099(22)00873-8	China	Therapeutics
Clin Infect Dis.	2023.02.12	<u>Infection-induced immunity is associated with protection against SARS-CoV-2 infection and decreased infectivity</u>	Frutos A.M., et al. https://doi.org/10.1093/cid/ciad074	Nicaragua / USA	Immunology
MMRW	2023.02.10	<u>COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022</u>	Johnson A.G., et al. http://dx.doi.org/10.15585/mmwr.mm7206a3	USA	Vaccines
Lancet Infect Dis.	2023.02.10	<u>Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study</u>	Aggarwal N.R., et al. https://doi.org/10.1016/S1473-3099(23)00011-7	USA	Therapeutics
Clin Infect Dis.	2023.02.09	<u>One-year Outcomes of Lung Transplantation for COVID-19 Associated End Stage Lung Disease in the United States</u>	Okumura K., et al. https://doi.org/10.1093/cid/ciad072	USA	Clinic
Lancet Regional Health Southeast Asia	2023.02.09	<u>Safety and efficacy of mycophenolate in COVID-19: a nonrandomised prospective study in western India</u>	Sajgure A., et al. https://doi.org/10.1016/j.lansea.2023.100154	India	Therapeutics
NEJM	2023.02.09	<u>Early Treatment with Pegylated Interferon Lambda for Covid-19</u>	Reis G., et al. https://doi.org/10.1056/NEJMoa2209760	International	Therapeutics
Nature Materials	2023.02.09	<u>An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection</u>	Mei X., et al. https://doi.org/10.1038/s41563-023-01475-7	USA	Therapeutics
Lancet Public Health	2023.02.09	<u>Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study</u>	Imai N., et al. https://doi.org/10.1016/S2468-2667(22)00337-1	UK	Public Health / Epidemiology
Lancet	2023.02.08	<u>Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis</u>	Pan Y., et al. https://doi.org/10.1016/S0140-6736(23)00129-0	China	Virology

medRxiv	2023.02.08	<u>A Phase 2, Randomized, Double-blind, Placebo-controlled Study of oral RP7214, a DHODH inhibitor, in Patients with Symptomatic Mild SARS-CoV-2 Infection</u>	Nair A., et al. https://doi.org/10.1101/2023.02.08.23285565	India	Therapeutics
Nature Commun.	2023.02.08	<u>Severe COVID-19 patients have impaired plasmacytoid dendritic cell-mediated control of SARS-CoV-2</u>	Venet M., et al. https://doi.org/10.1038/s41467-023-36140-9	France	Immunology
Nature Commun.	2023.02.08	<u>Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients</u>	Rouet R., et al. https://doi.org/10.1038/s41467-023-36295-5	Australia / Germany	Therapeutics
BMJ	2023.02.08	<u>Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study</u>	Jorgensen S.C.J., et al. https://doi.org/10.1136/bmj-2022-074035	Canada	Vaccines
Clin Infect Dis.	2023.02.08	<u>Relative effectiveness of COVID-19 vaccination and booster dose combinations among 18.9 million vaccinated adults during the early SARS-CoV-2 Omicron period — United States, January 1, 2022–March 31, 2022</u>	Kompaniyets L., et al. https://doi.org/10.1093/cid/ciad063	USA	Vaccines
medRxiv	2023.02.07	<u>Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France</u>	Tamandjou C., et al. https://doi.org/10.1101/2023.01.11.23284137	France	Public Health / Epidemiology
eClinicalMedicine	2023.02.05	<u>Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020–2022</u>	Nandi A., et al. https://doi.org/10.1016/j.eclinm.2023.101848	USA/Italy	Public Health / Epidemiology
eClinicalMedicine	2023.02.05	<u>Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study</u>	Liu J., et al. https://doi.org/10.1016/j.lanwpc.2023.100694	China	Therapeutics
Nature Commun.	2023.02.04	<u>Direct Cryo-ET observation of platelet deformation induced by SARS-CoV-2 spike protein</u>	Kuhn C.C., et al. https://doi.org/10.1038/s41467-023-36279-5	International	Immunology
JAMA NetwOpen	2023.02.03	<u>Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron</u>	Wei Y., et al., https://doi.org/10.1001/jamanetworkopen.2022.54777	Hong Kong	Vaccines
Clin Microbiol Infect.	2023.02.03	<u>The association of neonatal SARS-CoV-2 anti-spike protein receptor-binding domain antibodies at delivery with infant COVID-19 infection under age 6 months: a prospective cohort study</u>	Oz-Alkalay L, et al. https://doi.org/10.1016/j.cmi.2023.01.023	Israel	Clinic
Nature Commun.	2023.02.03	<u>Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity</u>	Chen WH., et al. https://doi.org/10.1038/s41467-023-36106-x	USA	Therapeutics
JAMA Network Open	2023.02.02	<u>Rates of and Factors Associated With Primary and Booster COVID-19 Vaccine Receipt by US Veterans, December 2020 to June 2022</u>	Bajema K.L., et al. https://doi.org/10.1001/jamanetworkopen.2022.54387	USA	Vaccines
Nature Commun.	2023.02.02	<u>High-depth sequencing characterization of viral dynamics across tissues in fatal COVID-19 reveals compartmentalized infection</u>	Normandin E., et al. https://doi.org/10.1038/s41467-022-34256-y	USA	Virology
Nat Commun	2023.02.02	<u>SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection</u>	Pušnik J., et al. https://doi.org/10.1038/s41467-023-36250-4	USA	Immunology
Eurosurveill.	2023.02.02	<u>Minimising school disruption under high incidence conditions due to the Omicron variant in France, Switzerland, Italy, in January 2022</u>	Colosi E., et al. https://doi.org/10.2807/1560-7917.ES.2023.28.5.2200192	France	Public Health / Epidemiology
Nature	2023.02.01	<u>Structural basis for substrate selection by the SARS-CoV-2 replicase</u>	Malone B.F., et al. https://doi.org/10.1038/s41586-022-05664-3	USA	Therapeutics

JAMA Netw Open	2023.02.01	Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States	Abara W.E., et al. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2800871	USA	Vaccines
Lancet Preprints	2023.01.31	Immunogenicity and Tolerability of BBV154 (iNCOVACC®), an Intranasal SARS-CoV-2 Vaccine, Compared with Intramuscular Covaxin® in Healthy Adults: A Randomised, Open-Label, Phase 3 Clinical Trial	Singh C., et al. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4342771	India	Vaccines
Clin Microbiol Infect.	2023.01.31	Bacillus Calmette-Guérin vaccine for prevention of COVID-19 and other respiratory tract infections in older adults with comorbidities: a randomized controlled trial	Koekenbier E.L., et al. https://doi.org/10.1016/j.cmi.2023.01.019	Netherlands	Vaccines
Nature Immunol.	2023.01.30	A patient-centric modeling framework captures recovery from SARS-CoV-2 infection	Ruffieux H., et al. https://doi.org/10.1038/s41590-022-01380-2	International	Immunology
JAMA Network Open	2023.01.30	Assessment of COVID-19 as the Underlying Cause of Death Among Children and Young People Aged 0 to 19 Years in the US	Flaxman S., et al. https://doi.org/10.1001/jamanetworkopen.2022.53590	International	Public Health / Epidemiology
Metabolism	2023.01.30	Early humoral response to COVID-19 vaccination in patients living with obesity and diabetes in France. The COVPOP OBEDIAB study with results from the ANRS0001S COV-POPART cohort	Bénédicte G., et al. https://doi.org/10.1016/j.metabol.2023.155412	France	Immunology
Lancet Infect. Dis.	2023.01.27	Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalised with COVID-19 (COVASP): a pragmatic, cluster-randomised, non-inferiority trial	Chen J.Z., et al. https://doi.org/10.1016/S1473-3099(22)00832-5	Canada	Clinic
Clin Infect Dis.	2023.01.27	Severe Fatigue and Persistent Symptoms at Three Months Following SARS-CoV-2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study	Gottlieb M., et al. https://doi.org/10.1093/cid/ciad045	USA	Long Covid
medRxiv	2023.01.24	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273	Lee I.T., et al. https://doi.org/10.1101/2023.01.24.23284869	UK / USA	Vaccines
medRxiv	2023.01.22	Safety of bivalent omicron-containing mRNA-booster vaccines: a nationwide cohort study	Andersson N.W., et al. https://doi.org/10.1101/2023.01.21.23284855	Denmark	Vaccines
medRxiv	2023.01.19	Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the Nordic countries	Andersson N.W., et al. https://doi.org/10.1101/2023.01.19.23284764	International	Vaccines
NEJM	2023.01.25	Effectiveness of Bivalent Boosters against Severe Omicron Infection	Lin D., et al. https://doi.org/10.1056/NEJMc2215471	USA	Vaccines
NEJM	2023.01.25	Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine	Zou J., et al. https://doi.org/10.1056/NEJMc2214916	USA	Vaccines
NEJM	2023.01.25	Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373	Alves K., et al. https://doi.org/10.1056/NEJMc2215509	USA	Vaccines
medRxiv	2023.01.25	Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers	Nugent C., et al. https://doi.org/10.1101/2023.01.22.23284881	USA	Vaccines
medRxiv	2023.01.25	Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study	Evans A., et al. https://doi.org/10.1101/2023.01.24.23284916	UK	Therapeutics
eBioMedicine	2023.01.24	Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study	Fong C.H., et al. https://doi.org/10.1016/j.ebiom.2023.104446	China	Vaccines

Cell Discov.	2023.01.23	<u>Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2</u>	Ai L., et al. https://doi.org/10.1038/s41421-022-00517-9	China	Vaccines
medRxiv	2023.01.22	<u>Comparative effectiveness of Paxlovid versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients: observational cohort study using the OpenSAFELY platform</u>	Zheng B., et al. https://doi.org/10.1101/2023.01.20.23284849	UK	Therapeutics
Sci. Rep.	2023.01.21	<u>Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages</u>	Bhiman J. N., et al. https://doi.org/10.1038/s41598-023-27698-x	South Africa/USA	Vaccines
eClinicalMedicine	2023.01.20	<u>COVID-19 pneumonia and the subsequent risk of getting active pulmonary tuberculosis: a population-based dynamic cohort study using national insurance claims databases</u>	Kumwichar P., et al. https://doi.org/10.1016/j.eclinm.2023.101825	Thailand	Clinic
Clin. Microbiol. Infect.	2023.01.20	<u>Vaccination against SARS-CoV-2 in pregnancy during the Omicron wave: the prospective cohort study of the Italian obstetric surveillance system</u>	Decenti E.C., et al. https://doi.org/10.1016/j.cmi.2023.01.013	Italy	Vaccines
Science Adv.	2023.01.20	<u>Altered host protease determinants for SARS-CoV-2 Omicron</u>	Chen J.F., et al. https://doi.org/10.1126/sciadv.add3867	China	Virology
PNAS	2023.01.20	<u>Mosaic RBD nanoparticles induce intergenus cross-reactive antibodies and protect against SARS-CoV-2 challenge</u>	Lee D.B., et al. https://doi.org/10.1073/pnas.2208425120	South Korea	Immunology
Nature Commun.	2023.01.19	<u>Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial</u>	Fong Y., et al. https://doi.org/10.1038/s41467-022-35768-3	USA	Immunology
NEJM	2023.01.19	<u>Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years</u>	Winokur P., et al. https://doi.org/10.1056/NEJMoa2213082	International	Vaccines
medRxiv	2023.01.19	<u>Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection</u>	Annukka A.R.A., et al. https://doi.org/10.1101/2023.01.18.23284742	USA	Long Covid
NEJM	2023.01.18	<u>Protection against Reinfection with the Omicron BA.2.75 Subvariant</u>	Chemaitelly H., et al. https://doi.org/10.1056/NEJMc2214114	Qatar	Immunology
NEJM	2023.01.18	<u>Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1</u>	Miller J., et al. https://doi.org/10.1056/NEJMc2214314	USA	Immunology
Nature Med.	2023.01.18	<u>Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naïve population</u>	Lau J.J., et al. https://doi.org/10.1038/s41591-023-02219-5	International	Vaccines
Nature Commun.	2023.01.18	<u>Impact of the Euro 2020 championship on the spread of COVID-19</u>	Dehning, J., et al. https://doi.org/10.1038/s41467-022-35512-x	Germany	Public health / Epidemiology
JAMA Netw Open	2023.01.18	<u>Persistent COVID-19 Symptoms at 6 Months After Onset and the Role of Vaccination Before or After SARS-CoV-2 Infection</u>	Richard S.A., et al. https://doi.org/10.1001/jamanetworkopen.2022.51360	USA	Long Covid
Ann Intern Med.	2023.01.18	<u>Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study</u>	Dryden-Peterson S., et al. https://doi.org/10.7326/M22-2141	USA	Therapeutics
Lancet Microbe	2023.01.18	<u>First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2</u>	Smit M.J., et al. https://doi.org/10.1016/S2666-5247(22)00337-8	Netherlands / Denmark	Vaccines

Lancet	2023.01.17	Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study	Villar J., et al. https://doi.org/10.1016/S0140-6736(22)02467-9	International	Vaccines
Nature Commun.	2023.01.16	Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa	Sun K., et al. https://doi.org/10.1038/s41467-022-35652-0	USA	Immunology
Nature Commun.	2023.01.13	Preclinical development of kinetin as a safe error-prone SARS-CoV-2 antiviral able to attenuate virus-induced inflammation	Souza T.M.L., et al. https://doi.org/10.1038/s41467-023-35928-z	Brazil	Therapeutics
Nature Med.	2023.01.13	Estimating the transmission dynamics of SARS-CoV-2 Omicron BF.7 in Beijing after the adjustment of zero-COVID policy in November - December 2022	Leung K., et al. https://doi.org/10.1038/s41591-023-02212-y	Hong Kong / China	Public health / Epidemiology
JAMA	2023.01.12	Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19	McCarthy M. et al., https://doi.org/10.1001/jama.2022.24100	USA	Therapeutics
Nature Commun.	2023.01.12	Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5	Tseng H.F., et al. https://doi.org/10.1038/s41467-023-35815-7	USA	Vaccines
Nature Commun.	2023.01.12	Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa	du Bruyn E., et al. https://doi.org/10.1038/s41467-022-35689-1	International	Immunology
eClinicalMedicine	2023.01.12	COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2	Szibert A.J., et al. https://doi.org/10.1016/j.eclinm.2022.101823	UK	Vaccines
BMJ	2023.01.11	Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study	Mizrahi B., et al. https://doi.org/10.1136/bmj-2022-072529	Israel	Long Covid
Lancet Reg Health Southeast Asia	2023.01.11	Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study	Kulkarni P.S., et al. https://doi.org/10.1016/j.lansea.2022.100139	India / Australia	Vaccines
Crit Care	2023.01.10	Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial	Trøseid M., et al. https://doi.org/10.1186/s13054-022-04205-8	International	Therapeutics
medRxiv	2023.01.04	Attitudes towards booster, testing and isolation, and their impact on COVID-19 response in winter 2022/2023 in France, Belgium, and Italy	De Meijere G., et al. https://doi.org/10.1101/2022.12.30.22283726	International/France	Preprint
Lancet preprints	2023.01.03	Effectiveness of the Bivalent mRNA Vaccine in Preventing Severe COVID-19 Outcomes: An Observational Cohort Study	Arbel R., et al. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4314067	Israel	Vaccines
Lancet Infect Dis.	2023.01.11	Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia	Fadlyana E. et al., https://doi.org/10.1016/S1473-3099(22)00800-3	Indonesia/Australia	Vaccines
Cell Rep.	2023.01.11	Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium	Callaway H. M. et al., https://doi.org/10.1016/j.celrep.2023.112014	USA	Variants
Sci Transl Med	2023.01.11	SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376	Heilmann E, et al. https://www.science.org/doi/10.1126/scitranslmed.abq7360	Austria / USA	Therapeutics
Nat Commun	2023.01.10	SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19	Stanevich, O.V., et al. https://doi.org/10.1038/s41467-022-34033-x	Russia	Long COVID

Nature Med.	2023.01.09	<u>A survey of COVID-19 vaccine acceptance across 23 countries in 2022</u>	Lazarus, J.V., et al. https://doi.org/10.1038/s41591-022-02185-4	International Study	Vaccines
Nature Neurosci.	2023.01.09	<u>Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate</u>	Villadiego, J., et al. https://doi.org/10.1038/s41593-022-01242-y	Spain	Vaccines
Nat Genet	2023.01.09	<u>SARS-CoV-2 diagnostic testing rates determine the sensitivity of genomic surveillance programs</u>	Han, A.X., et al. https://doi.org/10.1038/s41588-022-01267-w	Netherlands / Switzerland / USA	Public Health / Epidemiology
eBioMedicine	2023.01.09	<u>Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine</u>	Azzi L. et al., https://doi.org/10.1016/j.ebiom.2022.104435	Italy	Vaccines
Cell Rep.	2023.01.09	<u>SARS-CoV-2 Omicron subvariants Spike recognition and neutralization elicited after the third dose of mRNA vaccine</u>	Tauzin A. et al., https://doi.org/10.1016/j.celrep.2023.111998	Canada	Variants
Nature Commun.	2023.01.06	<u>A population-based matched cohort study of major congenital anomalies following COVID-19 vaccination and SARS-CoV-2 infection</u>	Calvert, C., et al. https://doi.org/10.1038/s41467-022-35771-8	UK / Scotland / New Zealand	Vaccines
Clin. Infect. Dis.	2023.01.06	<u>Relationships between social vulnerability and COVID-19 vaccination coverage and vaccine effectiveness</u>	Dalton A. F. et al., https://doi.org/10.1093/cid/ciad003	USA	Public Health / Epidemiology
Commun Med	2023.01.05	<u>Effectiveness of BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong</u>	Leung, D., et al. https://doi.org/10.1038/s43856-022-00233-1	Hong Kong	Vaccines
Nat Microbiol	2023.01.05	<u>Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2</u>	Yang, J., et al. https://doi.org/10.1038/s41564-022-01288-5	USA	Therapeutics
CanSino	2023.01.05	<u>Randomized, blinded and parallel controlled clinical study to evaluate the safety and immunogenicity of heterologous boosting with COVID-19 mRNA vaccine in adults aged 18 years and above who have received 3 doses of COVID-19 inactivated vaccine</u>	https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0105/2023010501701.pdf	Press release	Vaccines
Nature	2023.01.04	<u>Influenza vaccination reveals sex dimorphic imprints of prior mild COVID-19</u>	Sparks, R., et al. https://doi.org/10.1038/s41586-022-05670-5	USA	Immunology
Nature Commun.	2023.01.04	<u>B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response</u>	Andreano E., et al. https://doi.org/10.1038/s41467-022-35781-6	Italy	Vaccines
Sci Adv	2023.01.04	<u>Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19</u>	Wigerblad G, et al. https://doi.org/10.1126/sciadv.ade8272	USA	Therapeutics
Sci Transl Med	2023.01.04	<u>Vaccination with Span, an antigen guided by SARS-CoV-2 S protein evolution, protects against challenge with viral variants in mice</u>	Zhao Y, et al. https://doi.org/10.1126/scitranslmed.abo3332	China	Variants
medRxiv	2023.01.04	<u>Attitudes towards booster, testing and isolation, and their impact on COVID-19 response i winter 2022/2023 in France, Belgium, and Italy</u>	Meijere G. et al. https://doi.org/10.1101/2022.12.30.22283726	Italy/France	Public Health / Epidemiology
Commun Med	2023.01.03	<u>Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting</u>	Pan D.Z., et al. https://doi.org/10.1038/s43856-022-00232-2	USA	Vaccines
Nature Commun.	2023.01.03	<u>Evaluation of mortality attributable to SARS-CoV-2 vaccine administration using national level data from Qatar</u>	Butt A.A., et al. https://doi.org/10.1038/s41467-022-35653-z	Qatar / USA	Vaccines

Nat Commun	2023.01.03	The rapid and highly parallel identification of antibodies with defined biological activities by SLISY	Lu, S., et al. https://doi.org/10.1038/s41467-022-35668-6	USA	Immunology
Valneva	2022.12.30	Valneva Reports Further Heterologous Booster Data for its Inactivated COVID-19 Vaccine	https://valneva.com/press-release/valneva-reports-further-heterologous-booster-data-for-its-inactivated-covid-19-vaccine/	Press release	Vaccines
JAMA Netw Open	2022.12.29	Association of COVID-19 Vaccination Rates of Staff and COVID-19 Illness and Death Among Residents and Staff in US Nursing Homes	Sinha S. et al., https://doi.org/10.1001/jamanetworkopen.2022.49002	USA	Public Health / Epidemiology
JAMA Netw Open	2022.12.29	Mental Health Symptoms of University Students 15 Months After the Onset of the COVID-19 Pandemic in France	Wathelet M. et al., https://doi.org/10.1001/jamanetworkopen.2022.49342	France	Public Health / Epidemiology
Clin. Microbiol. Infect.	2022.12.29	Impact of vaccination on the presence and severity of symptoms of hospitalised patients with an infection by the omicron variant (B.1.1.529) of the SARS-cov-2 (subvariant BA.1)	Beraud G. et al., https://doi.org/10.1016/j.cmi.2022.12.020	International Study	Variants
Clin Infect Dis.	2022.12.29	SARS-CoV-2 infection history and antibody response to three COVID-19 mRNA vaccine doses	Herring M. K. et al., https://doi.org/10.1093/cid/ciac976	USA	Vaccines
N Engl J Med	2022.12.28	VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19	Cao Z, et al. https://www.nejm.org/doi/full/10.1056/NEJMoa2208822	China	Therapeutics
Nat Commun	2022.12.27	Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses	Li, M. et al. https://doi.org/10.1038/s41467-022-35642-2	China / Singapore	Immunology
Clin. Microbiol. Infect.	2022.12.27	Time to negative PCR conversion among high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated by Sotrovimab or Nirmatrelvir	Martin-Blondel G. et al., https://doi.org/10.1016/j.cmi.2022.12.016	International Study	Variants
eClinicalMedicine	2022.12.26	Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial	Akinosoglou K. et al., https://doi.org/10.1016/j.eclinm.2022.101785	Greece	Therapeutics
Lancet Regional Health Western Pacific	2022.12.23	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: A population-based study in Hong Kong	Zhou R. et al., https://doi.org/10.1016/j.lanwpc.2022.100660	Hong Kong/China	Vaccines
Synairgen	2022.12.23	Nebulised interferon beta-1a (SNG001) in hospitalised COVID-19: SPRINTER Phase III Study	https://www.synairgen.com/media/2022-12-23-sprinter-trial-results-published	Press release	Therapeutics
Science Adv.	2022.12.23	Manganese-coordinated mRNA vaccines with enhanced mRNA expression and immunogenicity induce robust immune responses against SARS-CoV-2 variants	Fan N, et al. https://doi.org/10.1126/sciadv.abq3500	China	Vaccines
Lancet	2022.12.22	Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial	Han, A.X., et al. https://doi.org/10.1016/S0140-6736(22)02597-1	UK / South Africa / USA	Therapeutics
Science Immunol.	2022.12.22	Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination	Irrgang P, et al. https://doi.org/10.1126/sciimmunol.ade2798	Germany	Vaccines
Sci Adv	2022.12.21	Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system	Zhou Y, et al. https://doi.org/10.1126/sciadv.add7197	Denmark	Therapeutics
Research square	2022.12.19	Beta variant COVID-19 protein booster vaccines elicit durable cross-neutralization against SARS-CoV-2 variants of concern in non-human primates	Pavot V., et al. https://doi.org/10.21203/rs.3.rs-2372287/v1	USA/France	Preprint

Nature Immunol.	2022.12.19	<u>Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children</u>	Xu Q. et al. https://doi.org/10.1038/s41590-022-01367-z	USA	Immunology
eBioMedicine	2022.12.19	<u>SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination</u>	Liew F., et al. https://doi.org/10.1016/j.ebiom.2022.104402	UK	Clinic
medRxiv	2022.12.19	<u>Evaluation of bivalent Omicron BA.1 booster vaccination after different priming regimens in healthcare workers (SWITCH ON): a randomized controlled trial</u>	Tan N., et al. https://doi.org/10.1101/2022.12.18.22283593	Netherlands	Vaccines
Clin Infect Dis.	2022.12.19	<u>Impact of SARS-CoV-2 variants on inpatient clinical outcome</u>	Robinson M.L., et al. https://doi.org/10.1093/cid/ciac957	USA	Clinic
eBioMedicine	2022.12.16	<u>The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees</u>	Van Coillie J., et al. https://doi.org/10.1016/j.ebiom.2022.104408	Netherlands	Vaccines
eBioMedicine	2022.12.16	<u>Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study</u>	Cognasse F., et al. https://doi.org/10.1016/j.ebiom.2022.104414	France	Clinic
JAMA	2022.12.16	<u>Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial</u>	Higgins A., et al. https://doi.org/10.1001/jama.2022.23257	International	Therapeutics
Nature	2022.12.15	<u>SARS-CoV-2 infection and persistence in the human body and brain at autopsy</u>	Stein S.R., et al. https://doi.org/10.1038/s41586-022-05542-y	USA	Clinic
Clin Infect Dis.	2022.12.15	<u>Prevalence of post-COVID Condition 12 Weeks after Omicron Infection Compared to Negative Controls and Association with Vaccination Status</u>	Nehle M., et al. https://doi.org/10.1093/cid/ciac947	Switzerland	Long Covid
Nature Commun.	2022.12.15	<u>Multi-omics identify falling LRRC15 as a COVID-19 severity marker and persistent pro-thrombotic signals in convalescence</u>	Gisby J.S., et al. https://doi.org/10.1038/s41467-022-35454-4	UK	Clinic
Cell	2022.12.15	<u>Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants</u>	Wang Q., et al. https://doi.org/10.1016/j.cell.2022.12.018	USA	Variants
JAMA Netw Open	2022.12.14	<u>Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age</u>	Khan F. L., et al. https://doi.org/10.1001/jamanetworkopen.2022.46915	USA	Vaccines
medRxiv	2022.12.14	<u>Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection</u>	Perez-Saez J., et al. https://doi.org/10.1101/2022.12.13.22283400	Switzerland / USA	Variants
Nature	2022.12.14	<u>The WHO estimates of excess mortality associated with the COVID-19 pandemic</u>	Msemburi W., et al. https://doi.org/10.1038/s41586-022-05522-2	International	Public Health / Epidemiology
Nature Immunol.	2022.12.14	<u>Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones</u>	Lima N.S., et al. https://doi.org/10.1038/s41467-022-35456-2	USA / Israel	Immunology
JAMA Netw Open	2022.12.13	<u>Hospitalizations Associated With Mental Health Conditions Among Adolescents in the US and France During the COVID-19 Pandemic</u>	Gutiérrez-Sacristan A., et al. https://doi.org/10.1001/jamanetworkopen.2022.46548	International	Clinic
Ann Intern Med.	2022.12.13	<u>Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System</u>	Dryden-Peterson S., et al. https://doi.org/10.7326/M22-2141	USA	Therapeutics
Nature Commun.	2022.12.13	<u>Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up</u>	Canetti M., et al. https://doi.org/10.1038/s41467-022-35480-2	Israel / USA	Vaccines

Lancet Infect Dis.	2022.12.12	Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study	Tsang N.N.Y., et al. https://doi.org/10.1016/S1473-3099(22)00732-0	Hong Kong	Vaccines
Nature Commun.	2022.12.12	Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England	Kirsebom F.C.M., et al. https://doi.org/10.1038/s41467-022-35168-7	UK	Vaccines
Lancet Regional Health Europe	2022.12.11	Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom	Hyams C., et al. https://doi.org/10.1016/j.lanepe.2022.100556	UK / USA	Vaccines
Immunity	2022.12.11	Immunoglobulin germline gene polymorphisms influence the function of SARS-CoV-2 neutralizing antibodies	Pushparaj P., et al. https://doi.org/10.1016/j.immuni.2022.12.005	Sweden	Immunology
Clin Microbiol Infect.	2022.12.09	Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers	Radner H., et al. https://doi.org/10.1016/j.cmi.2022.12.008	Austria	Therapeutics
Clin Infect Dis.	2022.12.09	Comparison of levels of nasal, salivary, and plasma antibody to SARS-CoV-2 during natural infection and after vaccination	Cohen J.I., et al. https://doi.org/10.1093/cid/ciac934	USA	Immunology
Clin Infect Dis.	2022.12.09	Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel	Prunas O., et al. https://doi.org/10.1093/cid/ciac315	Israel / USA	Vaccines
Nature Med.	2022.12.08	Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae	Thompson R.C., et al. https://doi.org/10.1038/s41591-022-02107-4	Switzerland / USA	Long Covid
NEJM	2022.12.07	Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB	Imai M., et al. https://doi.org/10.1056/NEJMc2214302	Japan	Therapeutics
medRxiv	2022.12.07	Apixaban following discharge in hospitalised adults with COVID-19: Preliminary results from a multicentre, open-label, randomised controlled platform clinical trial	Toshner M.R., et al. https://www.medrxiv.org/content/10.1101/2022.12.07.22283175v1	UK	Therapeutics
Clin Infect Dis.	2022.12.07	Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study	Mukae H., et al. https://doi.org/10.1093/cid/ciac933	Japan	Therapeutics
JAMA Netw Open	2022.12.06	Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir	Hung Wong G.L.H., et al. https://doi.org/10.1001/jamanetworkopen.2022.45086	China	Therapeutics
Nature	2022.12.05	FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2	Brevini T., et al. https://doi.org/10.1038/s41586-022-05594-0	International	Therapeutics
Lancet Regional Health Americas	2022.12.04	Severe COVID-19 outcomes in pediatrics: An observational cohort analysis comparing Alpha, Delta, and Omicron variants	Bahl A., et al. https://doi.org/10.1016/j.lana.2022.100405	USA	Variants
Cell	2022.12.02	SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming	Wu C-T., et al. https://doi.org/10.1016/j.cell.2022.11.030	USA	Virology
JAMA Netw Open	2022.12.01	Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States	Chokkalingam A.P., et al. https://doi.org/10.1001/jamanetworkopen.2022.42919	USA	Therapeutics
Nature Med.	2022.12.01	Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes	Zhang H., et al. https://doi.org/10.1038/s41591-022-02116-3	USA	Long Covid

Nature Immunol.	2022.12.01	Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4+ T cell recognition	Tye E.X.C., et al. https://doi.org/10.1038/s41467-022-34895-1	UK	Immunology
Science Transl Med.	2022.12.01	Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later	Milligan E.C., et al. https://doi.org/10.1126/scitranslmed.add6383	USA	Immunology
Clin Infect Dis.	2022.12.01	Trends in Cases, Hospitalization and Mortality Related to the Omicron BA.4/BA.5 Sub-Variants in South Africa	Jassat W., et al. https://doi.org/10.1093/cid/ciac921	South Africa	Public health / Epidemiology
Nature Commun.	2022.11.30	Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants	Magnusson K., et al. https://doi.org/10.1038/s41467-022-35240-2	International	Long Covid
Clin Infect Dis.	2022.11.30	Predictors of COVID-19 hospitalization after sotrovimab in hematologic malignancy patients during the BA.1 Omicron surge	Yan J., et al. https://doi.org/10.1093/cid/ciac916	USA	Therapeutics
JAMA Netw Open	2022.11.29	Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection	Garneau W.M., et al. https://doi.org/10.1001/jamanetworkopen.2022.44141	USA	Therapeutics
Ann Intern Med.	2022.11.29	Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial	Potter G.E.H., et al. https://doi.org/10.7326/M22-2116	USA	Therapeutics
Nature Commun.	2022.11.29	A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents	Dumont R., et al. https://doi.org/10.1038/s41467-022-34616-8	Switzerland / USA	Long Covid
Nature Commun.	2022.11.28	High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection	Jacobsen E.M., et al. https://doi.org/10.1038/s41467-022-35055-1	Germany / Austria	Immunology
Nature Commun.	2022.11.25	Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity	Smith N., et al. https://doi.org/10.1038/s41467-022-34895-1	France / Ireland	Immunology
Lancet Infect Dis.	2022.11.24	Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021–March, 2022: a national, observational, test-negative, case-control study	Powell A.A., et al. https://doi.org/10.1016/S1473-3099(22)00729-0	UK	Variants
BMJ	2022.11.23	Impact of community asymptomatic rapid antigen testing on covid-19 related hospital admissions: synthetic control study	Zhang X., et al. https://doi.org/10.1136/bmj-2022-071374	UK	Public Health / Epidemiology
PNAS	2022.11.23	Pandemic fatigue impedes mitigation of COVID-19 in Hong Kong	Du Z., et al. https://doi.org/10.1073/pnas.2213313119	China	Public Health / Epidemiology
medRxiv	2022.11.23	Changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States between December 2021 and November 2023	Klaassen F., et al. https://doi.org/10.1101/2022.11.19.22282525	USA	Variants
medRxiv	2022.11.23	Changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States between December 2021 and November 2022	Klaassen F., et al. https://doi.org/10.1101/2022.11.19.22282525	USA	Variants
Clin Infect Dis.	2022.11.22	AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19	Levin M.J., et al. https://doi.org/10.1093/cid/ciac899	UK / USA	Therapeutics
bioRxiv	2022.11.21	Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies	Planas D., et al. https://doi.org/10.1101/2022.11.17.516888	France	Variants
Nature Commun.	2022.11.19	Antigenic sin of wild-type SARS-CoV-2 vaccine shapes poor cross-neutralization of BA.4/5/2.75 subvariants in BA.2 breakthrough infections	Ju B., et al. https://doi.org/10.1038/s41467-022-34400-8	China	Variants

Pfizer/BioNTech	2022.11.18	<u>Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages</u>	https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-report-new-data-omicron-ba4ba5-adapted	Press release	Vaccines
BMJ	2022.11.16	<u>Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform</u>	Zheng B, et al. https://doi.org/10.1136/bmj-2022-071932	UK	Therapeutics
BMJ	2022.11.16	<u>Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial</u>	Zheng B, et al. https://doi.org/10.1136/bmj-2022-072175	International	Therapeutics
Lancet Respir Med.	2022.11.16	<u>In-hospital and 6-month outcomes in patients with COVID-19 supported with extracorporeal membrane oxygenation (EuroECMO-COVID): a multicentre, prospective observational study</u>	Lorusso R., et al. https://doi.org/10.1016/S2213-2600(22)00403-9	Italy	Clinic
Lancet Rheumatol.	2022.11.16	<u>Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study</u>	Bjørlykke K.H., et al. https://doi.org/10.1016/S2665-9913(22)00330-7	Norway	Immunology
Science Transl Med.	2022.11.16	<u>A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae</u>	George P.M., et al. https://doi.org/10.1126/scitranslmed.abo5795	UK	Clinic
NEJM	2022.11.16	<u>In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6</u>	Takashita E., et al. https://doi.org/10.1056/NEJMc2211845	Japan	Therapeutics
Lancet Regional Health Americas	2022.11.15	<u>Modeling the impact of child vaccination (5–11 y) on overall COVID-19 related hospitalizations and mortality in a context of omicron variant predominance and different vaccination coverage paces in Brazil</u>	Cardozo Müller G., et al. https://doi.org/10.1016/j.lana.2022.100396	Brazil	Vaccines
J Exp Med.	2022.11.15	<u>SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly</u>	Onnis A., et al. https://doi.org/10.1084/jem.20220906	Italy	Immunology
Nat Commun.	2022.11.15	<u>Effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy: a national observational study in Israel</u>	Guedalia, J. et al. https://doi.org/10.1038/s41467-022-34605-x	Israel	Vaccines
Ann Intern Med.	2022.11.15	<u>Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy</u>	McCreary E.K., et al. https://doi.org/10.7326/M22-1329	USA	Therapeutics
Science Immunol.	2022.11.15	<u>Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice</u>	Muik A., et al. https://doi.org/10.1126/sciimmunol.ade9888	Germany	Vaccines
Nat Commun.	2022.11.14	<u>Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents</u>	Wang, L., et al. https://doi.org/10.1038/s41467-022-34280-y	China	Vaccines
Moderna	2022.11.14	<u>Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to booster dose of mRNA-1273 in phase 2/3 clinical trial</u>	https://investors.modernatx.com/news/news-details/2022/Modernas-BA.4BA.5-Targeting-Bivalent-Booster-mRNA-1273.222-Meets-Primary-Endpoint-of-Superiority-Against-Omicron-Variants-Compared-to-Booster-Dose-of-mRNA-1273-in-Phase-23-Clinical-Trial/default.aspx	Press release	Vaccines
Lancet Regional Health Wester Pacific	2022.11.14	<u>Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna</u>	Brault A., et al. https://doi.org/10.1016/j.lanwpc.2022.100634	France	Public Health / Epidemiology

Clin Microbiol Infect.	2022.11.12	<u>Diagnostic accuracy of SARS-CoV-2 rapid antigen self-tests in asymptomatic individuals in the Omicron period: cross sectional study</u>	Venekamp R.P., et al. https://doi.org/10.1016/j.cmi.2022.11.004	Netherlands	Diagnostics
Nat Commun.	2022.11.11	<u>Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England</u>	Whitaker, M., et al. https://doi.org/10.1038/s41467-022-34244-2	UK	Variants
Nat Commun.	2022.11.11	<u>A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain</u>	Wang, J. et al. https://doi.org/10.1038/s41467-022-34633-7	China	Vaccines
JAMA Netw Open	2022.11.11	<u>Postdischarge Glucocorticoid Use and Clinical Outcomes of Multisystem Inflammatory Syndrome in Children</u>	Son M.B.F., et al. https://doi.org/10.1001/jamanetworkopen.2022.41622	USA	Clinic
Clin Microbiol Infect.	2022.11.11	<u>Real-life evaluation of a rapid antigen test (DPP® SARS-CoV-2 antigen) for COVID-19 diagnosis of primary healthcare patients, in the context of the omicron-dominant wave in Brazil</u>	Bezerra M.F., et al. https://doi.org/10.1016/j.cmi.2022.11.003	Brazil	Diagnostics
Clin Infect Dis.	2022.11.11	<u>VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including COVID-19 in the Elderly: a phase III randomised, double-blind, placebo-controlled, multicenter clinical study</u>	Blossey A.M., et al. https://doi.org/10.1093/cid/ciac881	Germany	Vaccines
Cell	2022.11.10	<u>Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in macaques</u>	Le Nouën C., et al. https://doi.org/10.1016/j.cell.2022.11.006	USA	Vaccines
Nature Commun.	2022.11.10	<u>Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters</u>	Liu, S., et al., https://doi.org/10.1038/s41467-022-34571-4	USA	Vaccines
JAMA Netw Open	2022.11.09	<u>Long-lasting Symptoms After an Acute COVID-19 Infection and Factors Associated With Their Resolution</u>	Robineau O., et al. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2798224	France	Long Covid
NEJM	2022.11.09	<u>Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose</u>	Canetti G., et al. https://doi.org/10.1056/NEJMc2211283	Israel	Vaccines
NEJM	2022.11.09	<u>Lifting Universal Masking in Schools — Covid-19 Incidence among Students and Staff</u>	Cowger T.L., et al. https://doi.org/10.1056/NEJMoa2211029	USA	Public Health / Epidemiology
Clin Infect Dis.	2022.11.09	<u>Maternal Antibody Response and Transplacental Transfer Following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection or Vaccination in Pregnancy</u>	Otero S., et al. https://doi.org/10.1093/cid/ciac793	USA	Immunology
bioRxiv	2022.11.09	<u>Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates.</u>	Marc A., et al. https://doi.org/10.1101/2022.11.09.515748	France	Variants
bioRxiv	2022.11.09	<u>Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages</u>	Xia H., et al. https://doi.org/10.1101/2022.11.08.515725	USA	Variants
Nature Commun.	2022.11.09	<u>Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study</u>	Etter M.M., et al. https://doi.org/10.1038/s41467-022-34068-0	Switzerland	Long Covid
Nature	2022.11.09	<u>Ferrobotic swarms enable accessible and adaptable automated viral testing</u>	Lin H., et al., https://doi.org/10.1038/s41586-022-05408-3	USA	Diagnostics
Nature	2022.11.09	<u>Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir</u>	Iketani S., et al., https://doi.org/10.1038/s41586-022-05514-2	USA	Therapeutics
Novavax	2022.11.08	<u>Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster</u>	https://ir.novavax.com/2022-11-08-Novavax-Phase-3-COVID-19-Omicron-Trial-Supports-the-Continued-and-Future-Use-of-Novavax-Prototype-Vaccine-as-a-Booster	Press release	Vaccines

medRxiv	2022.11.08	<u>Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine</u>	Yamamoto S., et al. https://doi.org/10.1101/2022.11.07.22282054	Japan	Vaccines
Lancet Regional Health West Pacific	2022.11.07	<u>Safety of BNT162b2 or CoronaVac COVID-19 vaccines in patients with heart failure: A self-controlled case series study</u>	Ye X., et al. https://doi.org/10.1016/j.lanwpc.2022.100630	Hong Kong	Vaccines
Nature Commun.	2022.11.07	<u>Viral load dynamics of SARS-CoV-2 Delta and Omicron variants following multiple vaccine doses and previous infection</u>	Woodbridge Y., et al., https://doi.org/10.1038/s41467-022-33096-0	Israel	Vaccines
medRxiv	2022.11.05	<u>Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19</u>	Xie Y., et al. https://doi.org/10.1101/2022.11.03.22281783	USA	Therapeutics
Pfizer	2022.11.04	<u>Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine</u>	https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-clinical-data-omicron	USA / Germany	Press release
Clin Infect Dis.	2022.11.04	<u>Twice daily oral zinc in the treatment of patients with Coronavirus Disease-19 A randomized double-blind controlled trial</u>	Ben Abdallah S., et al. https://doi.org/10.1093/cid/ciac807	Tunisia	Therapeutics
Nature	2022.11.03	<u>A multinational Delphi consensus to end the COVID-19 public health threat</u>	Lazarus J.V., et al. https://doi.org/10.1038/s41586-022-05398-2	International	Public Health
Nature Commun.	2022.11.03	<u>Immunomodulatory fecal metabolites are associated with mortality in COVID-19 patients with respiratory failure</u>	Stutz M.R., et al. https://doi.org/10.1038/s41467-022-34260-2	USA	Clinic
Science Transl Med.	2022.11.03	<u>S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters</u>	Saski M., et al. https://doi.org/10.1126/scitranslmed.abq4064	Japan	Therapeutics
Lancet Glob Health	2022.11.02	<u>High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: A randomized, phase 2, crossover trial</u>	Hansen K. S. et al., https://doi.org/10.1016/j.lanepe.2022.100539	Denmark	Therapeutics
JAMA Netw Open	2022.11.02	<u>COVID-19 Case Investigation and Contact Tracing in New York City, June 1, 2020, to October 31, 2021</u>	Blaney K. et al., https://doi.org/10.1001/jamanetworkopen.2022.39661	USA	Public Health
Nature	2022.11.02	<u>Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents</u>	Uraki R., et al. https://doi.org/10.1038/s41586-022-05482-7	Japan / USA	Variants
PNAS	2022.11.02	<u>Anti-PF4 antibodies associated with disease severity in COVID-19</u>	Liu Q., et al. https://doi.org/10.1073/pnas.2213361119	USA	Clinic
NEJM	2022.11.02	<u>Covid-19 Vaccine Protection among Children and Adolescents in Qatar</u>	Chemaitelly H., et al. https://doi.org/10.1056/NEJMoa2210058	Qatar	Vaccines
Akston Biosciences	2022.11.01	<u>Akston Biosciences Announces Positive Interim Phase II Results from COVID "Universal" Booster Vaccine Trial</u>	https://www.akstonbio.com/press-release-11-01-22/	USA	Press release
eBioMedicine	2022.11.01	<u>Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial</u>	Chandiwana N. et al., https://doi.org/10.1016/j.ebiom.2022.104322	South Africa	Therapeutics
Science Immunol.	2022.11.01	<u>Durable spike-specific T-cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination</u>	Maringer Y., et al. https://doi.org/10.1126/sciimmunol.add3899	Germany	Vaccines
Vaccine	2022.10.31	<u>Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study</u>	Thuluva S., et al. https://doi.org/10.1016/j.vaccine.2022.10.045	India	Vaccines

Clin Infect Dis.	2022.10.31	<u>Effectiveness of Evusheld in Immunocompromised Patients: Propensity Score-Matched Analysis</u>	Najjar-Debbiny R., et al. https://doi.org/10.1093/cid/ciac855	Israel	Therapeutics
Clin Infect Dis.	2022.10.31	<u>Adverse Events Following Immunization with mRNA and Viral Vector Vaccines in Individuals with Previous SARS-CoV-2 Infection from the Canadian National Vaccine Safety Network</u>	Bettinger J.A., et al. https://doi.org/10.1093/cid/ciac852	Canada	Clinic
BioRxiv	2022.10.28	<u>Tocilizumab treatment leads to early resolution of myeloid dysfunction and lymphopenia in patients hospitalized with COVID-19</u>	Shivram H. et al., https://doi.org/10.1101/2022.10.27.514096	USA	Therapeutics
Clin Infect Dis.	2022.10.28	<u>Differential patterns by area-level social determinants of health in COVID-19 related mortality and non-COVID-19 mortality: a population-based study of 11.8 million people in Ontario, Canada</u>	Wang L., et al. https://doi.org/10.1093/cid/ciac850	Canada	Public Health / Epidemiology
Clin Microbiol Infect.	2022.10.27	<u>Effect of COVID-19 infection and pandemic period on healthcare-associated infections acquired in intensive care units</u>	Lepape A. et al., https://doi.org/10.1016/j.cmi.2022.10.023	France	Clinic
Nature Med.	2022.10.27	<u>Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic</u>	Moore S., et al. https://doi.org/10.1038/s41591-022-02064-y	UK	Public Health / Epidemiology
Science	2022.10.27	<u>Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses</u>	Mao T., et al. https://doi.org/10.1126/science.abo2523	USA	Vaccines
Nature Microbiol.	2022.10.26	<u>Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial</u>	Choudhary M.C., et al. https://doi.org/10.1038/s41564-022-01254-1	USA	Therapeutics
Nature Commun.	2022.10.26	<u>Ultrafast one-minute electronic detection of SARS-CoV-2 infection by 3CLpro enzymatic activity in untreated saliva samples</u>	Borberg E., et al. https://doi.org/10.1038/s41467-022-34074-2	Israel	Diagnostics
BMJ	2022.10.26	<u>Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US</u>	Li X., et al. https://doi.org/10.1136/bmj-2022-071594	International	Vaccines
NEJM	2022.10.26	<u>Protection against Omicron from Vaccination and Previous Infection in a Prison System</u>	Chin E.T., et al. https://doi.org/10.1056/NEJMoa2207082	USA	Vaccines
BioRxiv	2022.10.25	<u>Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters</u>	Collier A.Y., et al. https://www.biorxiv.org/content/10.1101/2022.10.24.513619v1.full.pdf	USA	Vaccines
Inotrem	2022.10.25	<u>Inotrem announces that its ESSENTIAL Phase II study for the treatment of critically ill COVID-19 patients meets its primary and key secondary endpoints</u>	https://www.inotrem.com/wp-content/uploads/2022/10/Inotrem-announces-successful-Phase-II-study-for-critically-ill-COVID-19-patients.pdf	France	Press release
MGC Pharma	2022.10.25	<u>Long COVID Clinical Study Results for ArtemiC™ Support</u>	https://www.investi.com.au/api/announcements/mxc/f00d6627-732.html	Australia	Press release
Nature Commun.	2022.10.23	<u>Ablation of CD8+ T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3</u>	Swaminathan S., et al., https://doi.org/10.1038/s41467-022-34180-1	Australia	Variants
Nature Commun.	2022.10.23	<u>Detection and prevalence of SARS-CoV-2 co-infections during the Omicron variant circulation in France</u>	Bal A., et al. https://doi.org/10.1038/s41467-022-33910-9	France	Variants
American Society of Anesthesiologist	2022.10.22	<u>Regular use of common cholesterol-lowering drug linked to reduction of COVID-19 severity, risk of death</u>	https://www.eurekaalert.org/news-releases/967698	USA	Press release

MMRW	2022.10.21	<u>Effectiveness of Monovalent mRNA Vaccines Against COVID-19—Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022</u>	Surie D., et al. http://dx.doi.org/10.15585/mmwr.mm7142a3	USA	Vaccines
Clin Microbiol Infect.	2022.10.20	<u>Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.</u>	Karampitsakos T., et al. https://doi.org/10.1016/j.cmi.2022.10.015	Greece	Therapeutics
EClinicalMedicine	2022.10.20	<u>Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial</u>	McMahon J.H., et al. https://doi.org/10.1016/j.eclinm.2022.101703	Australia	Therapeutics
Lanc Infect Dis.	2022.10.20	<u>Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial</u>	Madhi S.A., et al. https://doi.org/10.1016/S1473-3099(22)00596-5	South Africa	Vaccines
Nature Med.	2022.10.20	<u>Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice</u>	Scheaffer S.M., et al. https://doi.org/10.1038/s41591-022-02092-8	USA	Vaccines
Moderna	2022.10.19	<u>90-Day Analysis Shows Moderna's Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster</u>	https://investors.modernatx.com/news/news-details/2022/90-Day-Analysis-Shows-Modernas-Omicron-BA.1-Targeting-Bivalent-Vaccine-mRNA-1273.214-Demonstrates-Superior-Antibody-Response-as-Fourth-Booster-Compared-to-Spikevax-Prototype-Booster/default.aspx	USA	Press release
NEJM	2022.10.19	<u>Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age</u>	Otiende M., et al., https://doi.org/10.1056/NEJMoa2209367	USA	Vaccines
Lancet Infect Dis.	2022.10.19	<u>Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial</u>	Khoo S.H., et al., https://doi.org/10.1016/S1473-3099(22)00644-2	UK	Therapeutics
Clin Infect Dis.	2022.10.19	<u>Severity of COVID-19 Hospitalization Outcomes and Patient Disposition Differ by Disability Status and Disability Type</u>	Clarke K.E.N., et al., https://doi.org/10.1093/cid/ciac826	USA	Clinic
Clin Microbiol Infect.	2022.10.19	<u>Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2, and cellular immune responses 3 months after booster vaccination</u>	Kazali Alidjinou E., et al., https://doi.org/10.1016/j.cmi.2022.10.014	France	Vaccines
NEJM	2022.10.19	<u>Myocarditis after BNT162b2 Vaccination in Israeli Adolescents</u>	Witberg G., et al. https://doi.org/10.1056/NEJMc2207270	Israel	Clinic
NEJM	2022.10.19	<u>Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6</u>	Hachmann N.P., et al. https://doi.org/10.1056/NEJMc2212117	USA	Variants
Nature Commun.	2022.10.18	<u>Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial</u>	Nevalainen O.P.O., et al https://doi.org/10.1038/s41467-022-33825-5	International	Therapeutics
Lancet Infect Dis.	2022.10.18	<u>Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark</u>	Holm Hansen C., et al., https://doi.org/10.1016/S1473-3099(22)00595-3	Denmark	Vaccines
Signal Transduct Target Ther.	2022.10.17	<u>Therapeutic strategy targeting host lipolysis limits infection by SARS-CoV-2 and influenza A virus</u>	Baek YB., et al. https://doi.org/10.1038/s41392-022-01223-4	Republic of Korea	Therapeutics
Nature Commun.	2022.10.17	<u>SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa</u>	Abdullahi A., et al. https://doi.org/10.1038/s41467-022-33792-x	International	Therapeutics

Lancet	2022.10.15	Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales	Agrawal U., et al., https://doi.org/10.1016/S0140-6736(22)01656-7	UK	Vaccines
Nature Aging	2022.10.14	Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults	Palacios-Pedrero M.Á., et al. https://doi.org/10.1038/s43587-022-00292-y	Germany / USA	Vaccines
Clin Microbiol Infect.	2022.10.14	One-month humoral response following two or three doses of mRNA Covid-19 vaccines as primary vaccination in specific populations in France: first results from the ANRS0001S COV-POPART cohort	Loubet P. et al., https://doi.org/10.1016/j.cmi.2022.10.009	France	Vaccines
Nature Med.	2022.10.13	Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection	Mentzer A.J., et al. https://doi.org/10.1038/s41591-022-02078-6	UK	Vaccines
Nature Commun.	2022.10.13	Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England	Webster H.H., et al. https://doi.org/10.1038/s41467-022-33740-9	UK	Clinic
medRxiv	2022.10.13	Impact of COVID-19 on mortality in coastal Kenya: a longitudinal open cohort study	Otiende M., et al. https://doi.org/10.1101/2022.10.12.22281019	Kenya/UK	Public Health / Epidemiology
Pfizer / BioNTech	2022.10.13	Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older	https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-announce-positive-early-data-clinical-trial	Germany / USA	Press release
BMJ	2022.10.13	Post-acute sequelae of covid-19 six to 12 months after infection: population based study	Peter R S, et al. https://doi.org/10.1136/bmj-2022-071050	Germany	Long Covid
Novavax	2022.10.13	Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains	https://ir.novavax.com/2022-10-13-Novavax-COVID-19-Influenza-Combination-Vaccine-Candidate-Induced-Antibody-and-T-Cell-Responses-Against-SARS-CoV-2-and-Homologous-and-Heterologous-Influenza-Strains	USA	Press release
Shionogi	2022.10.12	Development of an automatable highly sensitive method for coronavirus detection in wastewater (COPMAN method) —For acceleration of social implementation of wastewater-based epidemiology—	https://www.shionogi.com/global/en/news/2022/10/e-20221012.html	Japan	Press release
Nature Commun.	2022.10.12	Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19	de Prost N. et al. https://doi.org/10.1038/s41467-022-33801-z	France	Clinic
Nature Commun.	2022.10.12	Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study	Hastie C.E., et al. https://doi.org/10.1038/s41467-022-33415-5	UK	Long Covid
EBioMedicine	2022.10.12	Thrombopoietin participates in platelet activation in COVID-19 patients	Lupia E. et al., https://doi.org/10.1016/j.ebiom.2022.104305	Italy	Therapeutics
Lancet Respir Med.	2022.10.12	Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial	Eikelboom J. W. et al., https://doi.org/10.1016/S2213-2600(22)00298-3	Canada	Therapeutics
Novavax	2022.10.12	Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants	https://ir.novavax.com/2022-10-12-Novavax-Prototype-COVID-19-Vaccine-Data-Support-Homologous-and-Heterologous-Boosting-and-Suggest-Benefit-Against-Variants	USA	Press release

NEJM	2022.10.12	<u>Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2</u>	Ayoub H.H., et al. https://doi.org/10.1056/NEJMc2211055	Qatar	Immunology
Ann Intern Med.	2022.10.11	<u>Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era</u>	Ioannou G. N. et al., https://doi.org/10.7326/M22-1856	USA	Vaccines
JAMA	2022.10.10	<u>Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021</u>	Vos T. et al., https://doi.org/10.1001/jama.2022.18931	USA	Long Covid
EBioMedicine	2022.10.10	<u>Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial</u>	Madhavan M. et al., https://doi.org/10.1016/j.ebiom.2022.104298	UK	Vaccines
WHO	2022.10.10	<u>Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization – 3-6 October 2022</u>	https://cdn.who.int/media/docs/default-source/immunization/sage/2022/october/highlights_sage_oct_2022.pdf	International	Press release
Clin Infect Dis.	2022.10.10	<u>Safety and Efficacy of the NVX-CoV2373 COVID-19 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial</u>	Heath P.T., et al. https://doi.org/10.1093/cid/ciac803	USA	Vaccines
BMJ	2022.10.1	<u>Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study</u>	Adams K, et al. https://doi.org/10.1136/bmj-2022-072065	USA	Vaccines
Nature Commun.	2022.10.07	<u>The spike gene is a major determinant for the SARS-CoV-2 Omicron-BA.1 phenotype</u>	Barut G.T., et al. https://doi.org/10.1038/s41467-022-33632-y	Germany / Switzerland	Variants
Lancet Respir Med.	2022.10.07	<u>Pregnancy outcomes after SARS-CoV-2 infection in periods dominated by delta and omicron variants in Scotland: a population-based cohort study</u>	Stock S. J. et al., https://doi.org/10.1016/S2213-2600(22)00360-5	UK	Public Health / Epidemiology
Science Adv.	2022.10.07	<u>Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity</u>	Briquez P.S., et al. https://doi.org/10.1126/sciadv.abn3777	USA	Clinic
Nature Commun.	2022.10.06	<u>DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2</u>	Parzych, E.M., et al. https://doi.org/10.1038/s41467-022-33309-6	Canada / USA	Therapeutics
Nature Med.	2022.10.06	<u>Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial</u>	Chalkias S., et al. https://doi.org/10.1038/s41591-022-02031-7	USA	Vaccines
Linksbridge	2022.10.06	<u>Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): preliminary analysis from the United Kingdom randomised, controlled open-label, platform adaptive trial</u>	http://freepdfhosting.com/20cdd6cdfc.pdf	USA	Preprint
Merck	2022.10.06	<u>Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)</u>	https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-new-clinical-and-non-clinical-studies-of-lagevrio-molnupiravir/	USA	Press release
Science Adv.	2022.10.05	<u>Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody</u>	Kumar S., et al. https://doi.org/10.1126/sciadv.add2032	India	Virology
Clin Infect Dis.	2022.10.05	<u>Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV</u>	Fidler S., et al. https://doi.org/10.1093/cid/ciac796	UK	Vaccines

Nature	2022.10.05	SARS-CoV-2 disrupts host epigenetic regulation via histone mimicry	Kee, J. et al. https://doi.org/10.1038/s41586-022-05282-z	USA	Virology
Synairgen	2022.10.04	Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19	https://www.synairgen.com/media/data-from-the-us-nih-led-activ-2-phase-2-trial	UK	Press release
EBioMedicine	2022.10.04	Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2	Vogel E., et al. https://doi.org/10.1016/j.ebiom.2022.104294	Germany	Vaccines
EBioMedicine	2022.10.04	The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodelling	Ackermann M., et al. https://doi.org/10.1016/j.ebiom.2022.104296	Germany/UK	Clinic
Lancet Regional Health Western Pacific	2022.10.04	Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19	Ka-Chung Wai A., et al. https://doi.org/10.1016/j.lanwpc.2022.100602	China	Therapeutics
JAMA Netw Open	2022.10.03	Comparison of a Target Trial Emulation Framework vs Cox Regression to Estimate the Association of Corticosteroids With COVID-19 Mortality	Hoffman K. L., et al. https://doi.org/10.1001/jamanetworkopen.2022.34425	USA	Clinic
Clin Microbiol Infect.	2022.09.30	Prevalence of post-acute COVID-19 symptoms twelve months after hospitalisation in participants retained in follow-up: analyses stratified by gender from a large prospective cohort	Ghosn J., et al. https://doi.org/10.1016/j.cmi.2022.08.028	France	Long Covid
Nature Commun.	2022.09.29	Increased household transmission and immune escape of the SARS-CoV-2 Omicron compared to Delta variants	Jalali N., et al. https://doi.org/10.1038/s41467-022-33233-9	Norway	Public Health / Epidemiology
EClinicalMedicine	2022.09.28	Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial	Zhang Y., et al. https://doi.org/10.1016/j.eclinm.2022.101680	China	Vaccines
Lancet Infect Dis.	2022.09.28	Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12–17 years in Singapore: a national cohort study	Chiew C.J., et al. https://doi.org/10.1016/S1473-3099(22)00573-4	Singapore	Vaccines
Shionogi	2022.09.28	Shionogi Announces Achievement of the Primary Endpoint for Ensitrelvir Fumaric Acid (S-217622) in the Phase 3 part of the Phase 2/3 Clinical Trial in Asia	https://www.shionogi.com/global/en/news/2022/09/20220928.html	Japan	Press release
Cell	2022.09.27	Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses	Buckner C.M., et al. https://doi.org/10.1016/j.cell.2022.09.032	USA	Immunology
JAMA	2022.09.26	Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes	Lin D., et al. https://doi.org/10.1001/jama.2022.17876	USA	Vaccines
JAMA	2022.09.26	Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines	Kelly J.D., et al. https://doi.org/10.1001/jama.2022.17985	USA	Vaccines/Variants
JAMA Netw Open	2022.09.26	Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States	Schrag S.J., et al. https://doi.org/10.1001/jamanetworkopen.2022.33273	USA	Vaccines/Variants
Nature Commun.	2022.09.23	Household transmission of the SARS-CoV-2 Omicron variant in Denmark	Lyngse F.P., et al. https://doi.org/10.1038/s41467-022-33328-3	Denmark	Public Health / Epidemiology
bioRxiv	2022.09.23	Imprinted SARS-CoV-2 humoral immunity induces converging Omicron RBD evolution	Cao I., et al. https://doi.org/10.1101/2022.09.15.507787	China	Variants

Lancet Reg Health Americas	2022.09.23	<u>Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study</u>	Más-Bermejo P.I., et al. https://doi.org/10.1016/j.lana.2022.100366	Cuba	Vaccines
Science Transl Med.	2022.09.23	<u>SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages</u>	Martínez-Colón G.J., et al. https://doi.org/10.1126/scitranslmed.abm9151	USA	Clinic
Nature Med.	2022.09.22	<u>Long-term neurologic outcomes of COVID-19</u>	Xu E., et al. https://doi.org/10.1038/s41591-022-02001-z	USA	Clinic
Nature Immunol	2022.09.22	<u>Memory CD8+ T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination</u>	Brasu N., et al. https://doi.org/10.1038/s41590-022-01313-z	Italy	Vaccines
Clin Infect Dis.	2022.09.22	<u>Effectiveness of mRNA-1273 vaccine booster against COVID-19 in immunocompetent adults</u>	Florea A., et al. https://doi.org/10.1093/cid/ciac785	USA	Vaccines
Nature Commun.	2022.09.21	<u>The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition</u>	Motozono C., et al. https://doi.org/10.1038/s41467-022-33068-4	Japan	Vaccines
Nature Commun.	2022.09.21	<u>Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity</u>	Scurr M.J., et al. https://doi.org/10.1038/s41467-022-32985-8	UK	Immunology
eClinical Medicine	2022.09.21	<u>Effect of intravenous almitrine on intubation or mortality in patients with COVID-19 acute hypoxemic respiratory failure: A multicentre, randomised, double-blind, placebo-controlled trial</u>	Kalfon P., et al. https://doi.org/10.1016/j.eclinm.2022.101663	France	Clinic
Lancet Infect Dis.	2022.09.21	<u>Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study</u>	Carazo S., et al. https://doi.org/10.1016/S1473-3099(22)00578-3	Canada	Vaccines/Variants
Lancet Child Adolesc Health	2022.09.21	<u>Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study</u>	Kracalik I., et al. https://doi.org/10.1016/S2352-4642(22)00244-9	USA	Clinic
NEJM	2022.09.21	<u>IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination</u>	Thurner L., et al. https://doi.org/10.1056/NEJMc2205667	Germany	Clinic
Science Adv.	2022.09.21	<u>SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression</u>	Hashimoto R., et al. https://doi.org/10.1126/sciadv.abo6783	Japan	Virology
Clover	2022.09.20	<u>Clover's Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior Neutralization of Omicron BA.5 Compared to Inactivated Vaccine</u>	https://ir.cloverbiopharma.com/news-releases/news-release-details/clovers-universal-covid-19-booster-vaccine-candidate	China	Press release
Science Immunol.	2022.09.20	<u>Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5</u>	Muik A., et al. https://doi.org/10.1126/sciimmunol.ade2283	Germany	Immunology
Clin Infect Dis.	2022.09.20	<u>Associations of Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA-1273 Vaccine in COVE and TeenCOVE Trials</u>	Siangphoe U., et al. https://doi.org/10.1093/cid/ciac780	USA	Vaccines
JAMA	2022.09.20	<u>Effect of Helmet Noninvasive Ventilation vs Usual Respiratory Support on Mortality Among Patients With Acute Hypoxemic Respiratory Failure Due to COVID-19</u>	Arabi Y. M., et al., https://doi.org/10.1001/jama.2022.15599	Saudi Arabia	Clinic
Clin Microbiol Infect	2022.09.19	<u>Association between low response to rubella vaccination and reduced anti-SARS-CoV-2 immune response after vaccination with BNT162b2: A cross-sectional study</u>	Nakaharai K., et al., https://doi.org/10.1016/j.cmi.2022.09.007	Japan	Vaccines

PNAS	2022.09.19	Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein	Yang K., et al. https://doi.org/10.1073/pnas.2210990119	Finland / USA	Therapeutics
Clin Infect Dis.	2022.09.18	Comparative effectiveness of BNT162b2 and mRNA-1273 booster dose after BNT162b2 primary vaccination against the Omicron variants: A retrospective cohort study using large-scale population-based registries in Japan	Ono S., et al. https://doi.org/10.1093/cid/ciac763	Japan	Vaccines
J Infect Dis.	2022.09.17	Outcomes of Bebtelovimab Treatment is Comparable to Ritonavir-boosted Nirmatrelvir among High-Risk Patients with Coronavirus Disease-2019 during SARS-CoV-2 BA.2 Omicron Epoch	Razonable R.R., et al. https://doi.org/10.1093/infdis/jiac346	USA	Therapeutics
NEJM	2022.09.16	A Bivalent Omicron-Containing Booster Vaccine against Covid-19	Chalkias S, et al. https://doi.org/10.1056/NEJMoa2208343	USA	Vaccines
BioRxiv	2022.09.16	Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies	Sheward D. J., et al., https://doi.org/10.1101/2022.09.16.508299	Sweden	Variants
BMJ	2022.09.15	A living WHO guideline on drugs for covid-19	Agarwal A., et al. https://doi.org/10.1136/bmj.m3379	International	Therapeutics
Science	2022.09.15	The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance	Tegally H., et al. https://doi.org/10.1126/science.abq5358	International	Public Health / Epidemiology
eBioMedicine	2022.09.15	Protection against SARS-CoV-2 transmission by a parenteral prime—Intranasal boost vaccine strategy	Christensen D., et al. https://doi.org/10.1016/j.ebiom.2022.104248	Denmark / Sweden	Vaccines
Lancet	2022.09.14	The Lancet Commission on lessons for the future from the COVID-19 pandemic	Sachs J.D., et al. https://doi.org/10.1016/S0140-6736(22)01585-9	International	Vaccines
Lancet Infect Dis.	2022.09.14	Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study	Amir O., et al. https://doi.org/10.1016/S1473-3099(22)00527-8	Israel	Vaccines
NEJM	2022.09.14	Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection	Havervall S., et al. https://doi.org/10.1056/NEJMc2209651	Sweden	Immunology
NEJM	2022.09.14	Vaccine-Induced Immune Thrombocytopenia and Thrombosis after the Sputnik V Vaccine	Lane S., et al. https://doi.org/10.1056/NEJMc2210813	Argentina / UK	Vaccines
Cell	2022.09.14	Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants including BA.4 and BA.5	Kimura I., et al. https://doi.org/10.1016/j.cell.2022.09.018	Japan	Variants
NEJM	2022.09.14	Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa	Collie S., et al. https://doi.org/10.1056/NEJMc2210093	South Africa	Vaccines
Ann Intern Med.	2022.09.13	Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine Against Omicron Variant Among Elderly People in Singapore	Tan C.Y., et al. https://doi.org/10.7326/M22-2042	Singapore	Vaccines
Lancet Infect Dis.	2022.09.09	Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial	Hardt K., et al. https://doi.org/10.1016/S1473-3099(22)00506-0	Belgium	Vaccines
Clin Microbiol Infect.	2022.09.09	Evaluating the Efficacy and Safety of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 Spike Protein Vaccine: A Phase 3 Randomized Placebo-Controlled Trial	Tabarsi P, et al. https://doi.org/10.1016/j.cmi.2022.09.001	Australia / Iran	Vaccines

JAMA	2022.09.08	<u>Analysis of Vaccine Reactions After COVID-19 Vaccine Booster Doses Among Pregnant and Lactating Individuals</u>	Kachikis A., et al. https://doi.org/10.1001/jamanetworkopen.2022.30495	Israel / USA	Vaccines
Nature Com	2022.09.08	<u>The impact of repeated rapid test strategies on the effectiveness of at-home antiviral treatments for SARS-CoV-2</u>	Menkir T.F., et al. https://doi.org/10.1038/s41467-022-32640-2	UK / USA	Public health / Epidemiology
PNAS	2022.09.08	<u>A single-administration therapeutic interfering particle reduces SARS-CoV-2 viral shedding and pathogenesis in hamsters</u>	Chaturvedi S., et al. https://doi.org/10.1073/pnas.2204624119	USA	Therapeutics
Science Transl Med.	2022.09.07	<u>Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models</u>	Hajnik R.L., et al. https://doi.org/10.1126/scitranslmed.abq1945	USA	Vaccines
Lancet Respir Med.	2022.09.07	<u>Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial</u>	Vlaar A.P.J., et al. https://doi.org/10.1016/S2213-2600(22)00297-1	International	Therapeutics
BMJ	2022.09.07	<u>Prevention of covid-19 and other acute respiratory infections with cod liver oil supplementation, a low dose vitamin D supplement: quadruple blinded, randomised placebo controlled trial</u>	Brunvoll S.H., et al. https://doi.org/10.1136/bmj-2022-071245	Norway	Therapeutics
Clover	2022.09.06	<u>Clover's COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine</u>	https://ir.cloverbiopharma.com/news-releases/news-release-details/clovers-covid-19-vaccine-candidate-demonstrates-superior-booster	China	Press Release
Nature Med	2022.09.05	<u>Long-term cardiac pathology in individuals with mild initial COVID-19 illness</u>	Puntmann V.O., et al. https://doi.org/10.1038/s41591-022-02000-0	Germany	Long Covid
Lancet Infect Dis.	2022.09.05	<u>Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial</u>	Lazarus R., et al. https://doi.org/10.1016/S1473-3099(22)00502-3	UK	Vaccines
medRxiv	2022.08.31	<u>A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in Adults</u>	Lien C.E., et al. https://doi.org/10.1101/2022.08.29.22279317	Taiwan	Vaccines
Nature Med.	2022.11.10	<u>Acute and postacute sequelae associated with SARS-CoV-2 reinfection</u>	Bowe B., et al. https://doi.org/10.1038/s41591-022-02051-3	USA	Long Covid